3M announces the availability of immune response modifier compounds for nonvaccine use in the pharmaceutical industry. The toll-like receptor (TLR) compounds, that activate through TLR7 and TLR8, show promise for the treatment of conditions including cancer, dermatologic diseases and atopic diseases, such as allergy and asthma.
“These compounds have the potential to help patients that suffer from a variety of disease states making them a very valuable tool to the pharmaceutical industry”
The immune response modifiers available for license broaden 3M's existing offerings of TLR agonists for use as vaccine adjuvants by adding the option of monotherapy.
"These compounds have the potential to help patients that suffer from a variety of disease states making them a very valuable tool to the pharmaceutical industry" said Mark Tomai, PhD, Director of Vaccine Business Development at 3M Drug Delivery Systems.
For more information on licensing the IRMs, contact Dr. Mark Tomai at [email protected] or (651) 733-5375.
New urine-based test improves identification of high-grade prostate cancer